United Therapeutics Corporation
UTHRNASDAQHealthcareDrug Manufacturers - Specialty & Generic
As of Oct 23, 2026 close
- Market cap
- $26.91B
- P/E (TTM)
- 20.53
- Forward P/E
- 19.89
- Dividend yield
- -
- 52-week range
- $409.07$609.35
- Volume (live)
- -
- Avg. volume (3M)
- 913.17K
United Therapeutics (UTHR) Stock Price & Financial Analysis
United Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $576.24 - $590.98 |
|---|---|
| 52-Week High | $609.35 |
| 52-Week Low | $409.07 |
| Open | $584.92 |
| Volume (last close) | 637.86K |
| Average Volume (3M) | 913.17K |
| Revenue (TTM) | 3.15B |
|---|---|
| Net Income (TTM) | 1.31B |
| Free Cash Flow (TTM) | 1.09B |
| EPS (TTM) | $27.86 |
| Profit Margin | 41.56% |
| Operating Margin | 44.49% |
| Return on Equity (ROE) | 20.48% |
| Debt to Equity | 0.00 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 26.91B |
|---|---|
| Shares Outstanding | 45.80M |
| P/E Ratio (TTM) | 20.53 |
| Forward P/E | 19.89 |
| Price to Sales (P/S) | 8.53 |
| Price to Book (P/B) | 4.20 |
| EV/EBITDA | 15.31 |
| 50-Day MA | $515.23 |
|---|---|
| 200-Day MA | $527.57 |
| 1-Year Change | +37.21% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
United Therapeutics at a Glance
As of the Oct 23, 2026 close, United Therapeutics (UTHR) has a market capitalization of $26.91B. The stock trades at 20.5× trailing earnings, 19.9× forward earnings and 8.5× sales. Over the trailing twelve months it earned $1.31B on revenue of $3.15B (a 41.6% profit margin) and generated $1.09B of free cash flow. Revenue grew 2.5% year over year.
As of its latest reported balance sheet, it holds $1.80B in cash and securities against $0.00 of debt, a net cash position of $1.80B.
United Therapeutics does not currently pay a dividend.
The share price is up 37.2% over the past year. At $587.50 (the Oct 23, 2026 close) it sits near the top of its 52-week range of $409.07 to $609.35, above its 200-day moving average of $527.57.
Based on 17 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $659.57, 12.3% above the Oct 23, 2026 close.
Frequently Asked Questions About United Therapeutics
What is the current stock price for UTHR?
As of the Oct 23, 2026 close, UTHR stock trades at $587.50. The 52-week range is $409.07–$609.35, with a day range of $576.24–$590.98.
What is the P/E ratio for UTHR?
As of the Oct 23, 2026 close, United Therapeutics's trailing twelve-month (TTM) P/E ratio is 20.5, meaning investors pay $20.5 for every $1 of annual earnings. The forward P/E is 19.9, reflecting analyst expectations for future earnings. United Therapeutics operates in the Healthcare sector.
Does UTHR pay dividends?
United Therapeutics does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for UTHR?
Based on ratings from 17 professional analysts over the last 90 days, the consensus for UTHR is Buy. The average 12-month price target is $659.57, a 12.3% upside from the Oct 23, 2026 close of $587.50.
What is the market cap of UTHR?
As of the Oct 23, 2026 close, United Therapeutics's market capitalization is $26.91B, classifying it as a large-cap company. United Therapeutics operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.